Brilinta

E505483

P2Y12 receptor antagonist antiplatelet medication pharmaceutical drug platelet aggregation inhibitor

Brilinta is a prescription antiplatelet medication (ticagrelor) used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome or a history of myocardial infarction.

Try in SPARQL Jump to: Surface forms Disambiguation Statements Elicitation Referenced by

All labels observed (2)

Label	Occurrences
ticagrelor	2
Brilinta canonical	1

How this entity was disambiguated

This entity first appeared as the object of triple T5248764 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.

NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07

Target entity: Brilinta
Context triple: [AstraZeneca, notableProduct, Brilinta]

A. Xarelto
Xarelto is a widely used prescription anticoagulant (blood thinner) that helps prevent and treat blood clots and reduce the risk of stroke in certain patients.
B. apixaban
Apixaban is an oral anticoagulant (factor Xa inhibitor) used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions such as atrial fibrillation.
C. dabigatran
Dabigatran is an oral direct thrombin inhibitor anticoagulant used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions like atrial fibrillation.
D. Activase
Activase is a brand-name form of the clot-dissolving drug alteplase, widely used as a thrombolytic treatment for acute ischemic stroke and certain types of heart attack and pulmonary embolism.
E. Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
F. None of above. chosen
G. Unsure - the case is ambiguous/there is not enough information to decide.

NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07

Target entity: Brilinta
Target entity description: Brilinta is a prescription antiplatelet medication (ticagrelor) used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome or a history of myocardial infarction.

A. Xarelto
Xarelto is a widely used prescription anticoagulant (blood thinner) that helps prevent and treat blood clots and reduce the risk of stroke in certain patients.
B. apixaban
Apixaban is an oral anticoagulant (factor Xa inhibitor) used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions such as atrial fibrillation.
C. dabigatran
Dabigatran is an oral direct thrombin inhibitor anticoagulant used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions like atrial fibrillation.
D. Activase
Activase is a brand-name form of the clot-dissolving drug alteplase, widely used as a thrombolytic treatment for acute ischemic stroke and certain types of heart attack and pulmonary embolism.
E. Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
F. None of above. chosen

Statements (48)

Predicate	Object
instanceOf	P2Y12 receptor antagonist ⓘ antiplatelet medication ⓘ pharmaceutical drug ⓘ platelet aggregation inhibitor ⓘ
affectsBiologicalProcess	platelet aggregation ⓘ
approvedBy	U.S. Food and Drug Administration ⓘ linked to: Food and Drug Administration
commonAdverseEffect	bleeding ⓘ bruising ⓘ dyspnea ⓘ epistaxis ⓘ
contraindicatedIn	active pathological bleeding ⓘ history of intracranial hemorrhage ⓘ
contraindicatedWith	strong CYP3A4 inducers ⓘ strong CYP3A4 inhibitors ⓘ
developedBy	AstraZeneca ⓘ
firstApprovedYearUS	2011 ⓘ
hasActiveIngredient	ticagrelor ⓘ linked to: Brilinta
hasAdministrationFrequency	twice daily ⓘ
hasATCCode	B01AC24 ⓘ
hasBlackBoxWarning	risk of bleeding ⓘ
hasDosageForm	oral tablet ⓘ
hasDrugClass	P2Y12 inhibitor ⓘ antiplatelet agent ⓘ platelet aggregation inhibitor ⓘ
hasGenericName	ticagrelor ⓘ linked to: Brilinta
hasHalfLife	approximately 7 hours for ticagrelor ⓘ approximately 9 hours for active metabolite ⓘ
hasMechanismOfAction	reversible inhibition of P2Y12 ADP receptor on platelets ⓘ
hasRouteOfAdministration	oral ⓘ
hasStrength	60 mg tablet ⓘ 90 mg tablet ⓘ
indicatedFor	ST-elevation myocardial infarction ⓘ acute coronary syndrome ⓘ history of myocardial infarction ⓘ non–ST-elevation myocardial infarction ⓘ reduction of cardiovascular death ⓘ reduction of heart attack risk ⓘ reduction of stroke risk ⓘ unstable angina ⓘ
isPrescriptionOnly	true ⓘ
marketedAs	Brilique ⓘ Possia ⓘ
metabolizedBy	CYP3A4 ⓘ CYP3A5 ⓘ
pregnancyCategoryUS	not assigned (use only if clearly needed) ⓘ
reduces	platelet activation ⓘ
requiresCoAdministration	low-dose aspirin in most indications ⓘ
usedWith	aspirin ⓘ

How these facts were elicited

Referenced by (3)

Full triples — surface form annotated when it differs from this entity's canonical label.

AstraZeneca → notableProduct → Brilinta ⓘ

Brilinta → hasGenericName → ticagrelor ⓘ

linked to: Brilinta

Brilinta → hasActiveIngredient → ticagrelor ⓘ